253 related articles for article (PubMed ID: 21859946)
21. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
22. Levofloxacin cures experimental pneumonic plague in African green monkeys.
Layton RC; Mega W; McDonald JD; Brasel TL; Barr EB; Gigliotti AP; Koster F
PLoS Negl Trop Dis; 2011 Feb; 5(2):e959. PubMed ID: 21347450
[TBL] [Abstract][Full Text] [Related]
23. The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague.
Sebbane F; Jarrett C; Gardner D; Long D; Hinnebusch BJ
Infect Immun; 2009 Mar; 77(3):1222-9. PubMed ID: 19103769
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.
Frean JA; Arntzen L; Capper T; Bryskier A; Klugman KP
Antimicrob Agents Chemother; 1996 Nov; 40(11):2646-7. PubMed ID: 8913481
[TBL] [Abstract][Full Text] [Related]
25. [Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen].
Samokhodkina ED; Shcherbaniuk AI; Ryzhko IV; Tsuraeva RI; Skalyga EIu
Antibiot Khimioter; 2002; 47(3):26-9. PubMed ID: 16127904
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Ryzhko IV; Tsuraeva RI; Anisimov BI; Trishina AV
Antibiot Khimioter; 2009; 54(5-6):37-40. PubMed ID: 20052916
[TBL] [Abstract][Full Text] [Related]
27. Biovar-related differences apparent in the flea foregut colonization phenotype of distinct Yersinia pestis strains do not impact transmission efficiency.
Lemon A; Sagawa J; Gravelle K; Vadyvaloo V
Parasit Vectors; 2020 Jul; 13(1):335. PubMed ID: 32611387
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92.
Agar SL; Sha J; Foltz SM; Erova TE; Walberg KG; Parham TE; Baze WB; Suarez G; Peterson JW; Chopra AK
Microbiology (Reading); 2008 Jul; 154(Pt 7):1939-1948. PubMed ID: 18599822
[TBL] [Abstract][Full Text] [Related]
29. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
30. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.
Sun W; Roland KL; Kuang X; Branger CG; Curtiss R
Infect Immun; 2010 Mar; 78(3):1304-13. PubMed ID: 20086087
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92.
Agar SL; Sha J; Foltz SM; Erova TE; Walberg KG; Baze WB; Suarez G; Peterson JW; Chopra AK
Microbes Infect; 2009 Feb; 11(2):205-14. PubMed ID: 19073275
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.
Sofer-Podesta C; Ang J; Hackett NR; Senina S; Perlin D; Crystal RG; Boyer JL
Infect Immun; 2009 Apr; 77(4):1561-8. PubMed ID: 19124600
[TBL] [Abstract][Full Text] [Related]
33. [Yersinia pestis as a dangerous biological weapon].
Grygorczuk S; Hermanowska-Szpakowicz T
Med Pr; 2002; 53(4):343-8. PubMed ID: 12474416
[TBL] [Abstract][Full Text] [Related]
34. Oral vaccination against plague using Yersinia pseudotuberculosis.
Demeure CE; Derbise A; Carniel E
Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
[TBL] [Abstract][Full Text] [Related]
35. Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis.
Hau D; Wade B; Lovejoy C; Pandit SG; Reed DE; DeMers HL; Green HR; Hannah EE; McLarty ME; Creek CJ; Chokapirat C; Arias-Umana J; Cecchini GF; Nualnoi T; Gates-Hollingsworth MA; Thorkildson PN; Pflughoeft KJ; AuCoin DP
PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010287. PubMed ID: 35320275
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Neutrophil Primary Granule Release during Yersinia pestis Pulmonary Infection.
Eichelberger KR; Jones GS; Goldman WE
mBio; 2019 Dec; 10(6):. PubMed ID: 31822588
[TBL] [Abstract][Full Text] [Related]
37. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.
Bonacorsi SP; Scavizzi MR; Guiyoule A; Amouroux JH; Carniel E
Antimicrob Agents Chemother; 1994 Mar; 38(3):481-6. PubMed ID: 8203841
[TBL] [Abstract][Full Text] [Related]
38. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
[TBL] [Abstract][Full Text] [Related]
39. Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.
Andersson JA; Sha J; Kirtley ML; Reyes E; Fitts EC; Dann SM; Chopra AK
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109161
[TBL] [Abstract][Full Text] [Related]
40. Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
D'Arco C; McCormick AA; Arnaboldi PM
Vaccine; 2021 Mar; 39(9):1435-1444. PubMed ID: 33531196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
